#donanemab — Public Fediverse posts

https://www.europesays.com/ie/484075/ Price reductions needed to make groundbreaking Alzheimer’s drugs available – study #Alzheimer'sDisease #dementia #donanemab #Éire #Health #IE #Ireland #Lecanemab

‘Hopeful milestone’: Health Canada approves 2nd drug to slow Alzheimer’s – National

Health Canada has approved a second drug that can slow the progression of Alzheimer’s disease. Donanemab, sold by…
#NewsBeep #News #Healthcare #alzheimers #CA #Canada #donanemab #EliLilly #Health #HealthCanada
https://www.newsbeep.com/ca/658194/

‘Hopeful milestone’: Health Canada approves 2nd drug to slow Alzheimer’s

https://fed.brid.gy/r/https://globalnews.ca/news/11828976/health-canada-second-drug-alzheimers/

Will this be the death knell for Alzheimer’s monoclonal antibody treatments 🤔

Preprint on #Alzheimers drug deaths ignites dispute among authors

“Infighting among a group of prominent Alzheimer’s disease researchers has led to the withdrawal of a preprint they co-authored, which suggested a new Alzheimer’s drug markedly increases the risk of death. One scientist involved in the work charges the senior author failed to seek the go-ahead from his co-authors before posting an edited version of the article to a preprint server.”

#Lecanemab #Donanemab #Kisunla #amyloid #dementia
https://www.science.org/content/article/preprint-alzheimer-s-drug-deaths-ignites-dispute-among-authors

Do we have #Alzheimer’s disease all wrong?

“As Science noted in its story on the retracted paper, scientists are still debating whether the #amyloid theory is viable. The skeptics cite the fraudulent research and lack of a genuine breakthrough; supporters can point to this new class of drugs including #donanemab that have led to some improvement in some patients.”

https://www.vox.com/future-perfect/355108/alzheimers-disease-drug-approval-research-retraction

Two Is Better Than One in the Alzheimer’s Market

“Last week, a panel of independent advisers to the FDA unanimously voted in support of Eli Lilly’s #donanemab, a competitor in the same class of drugs that target #amyloid plaques in the brain. The #FDA is expected to decide on whether to approve the drug by the end of the year.

Life expectancies around the world have surged in recent decades, increasingly putting people at risk of #dementia. About one in nine seniors has #Alzheimer’s disease, the most common cause of the condition, which works out to some seven million Americans.”

https://finance.yahoo.com/news/two-better-one-alzheimer-market-110000384.html

Disease Modifying Therapy for #Alzheimer's #Dementia

"The long-awaited era of disease-modifying therapy for Alzheimer’s disease has finally arrived and will substantially impact how the disease is perceived and managed. The drugs closest to widespread clinical implementation are #lecanemab and #donanemab—intravenous #MonoclonalAntibodies that remove β #amyloid plaques from the #brain and can slow cognitive and functional decline."
#leqembi
https://cnmri.com/2023/07/21/disease-modifying-therapy-for-alzheimers/

Bayer’s oncology business looks to collect $10B in sales by 2030 — Some experts say FDA made the right call on Lilly's donanemab — Promising IPF treatment results sent Pliant Therapeutics stock soaring -- See more on our front page news http://bit.ly/w28kSd #bayer #oncology #prostatecancer #fda #elililly #donanemab #alzheimers #ipf #pharmanews #pharma #biotech #biotechnology #biopharma #cafepharma